PATENT

ICE RECEIVED

TECH CENTER 1600/2900 Attorney Docket No.: 47508.556 (HYZ-069CN2)

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Sudhir Agrawal

Serial No.:

09/896,692

Examiner: Jane J. Zara

Filed:

June 29, 2001

Group Art Unit: 1635

For:

NOVEL HIV-SPECIFIC OLIGONUCLEOTIDES AND METHODS OF

THEIR USE

CERTIFICATE OF FIST CLASS MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below

****** ************

Assistant Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant and their attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97(c) hereby submit these publications for the Examiner's consideration along with the required fee of \$180 as set forth in $\S1.97(c)(2)$ and $\S1.17(p)$.

In addition, we are re-submitting under "Other Documents" reference A21, Milner et al. (1997) "Selecting Effective Antisense Reagents On Combinatorial Oligonucleotide Arrays," Nature Biotech. 15:537-541, due to a typo of the year (1977) in the initial IDS filed on September 5, 2001.

00000090 080219 09896692 02/06/2004 HALI11

02 FC:1806

180.00 DA

Appl. No. 09/896,692	Atty. Docket No. 47508.556
Reply to Office Action of October 2, 2003	Client Ref. No. HYZ-069CN2

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

The Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. <u>08-0219</u>.

Respectfully submitted,

Date: February 2, 2004

James T. Olesen, Ph.D. Registration No. 46,967 Attorney for Applicant

Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109

Tel: (617) 526-6045 Fax: (617) 526-5000

Application Number Subt. Form PTO-1449 Docket Number 47508-556 09/896,692 NFORMATION DISCLOSURE OF IN AN APPLICATION (HYZ-069CN2) Applicant Agrawal 0 4 2004 (e several sheets if necessary) FEB Group Art Unit Filing Date OF 2 1 June 29, 2001 1635

		U.	S. Patent Documer	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,806,463	05/1986	Goodchild et al.	435	5	
	5,470,702	01/1993	Hovanessian et al.	435	5	
	5,591,721	10/1994	Agrawal et al.	514	44	
	5,652,355	07/1997	Metelev et al.	536	24.5	
	5,652,356	07/1997	Agrawal	536	24.5	
	6,608,035	08/2003	Agrawal et al.	514	44	
	6,645,943	11/2003	Agrawal et al.	514	44-	

		Forei	gn Patent Docur	nents			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO YES N	LATION NO
	WO96/12497	05/02/96	PCT				
	WO 98/40058	9/17/1998	PCT				

	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
<u>, </u>	
A1	Agrawal, et al. (1992) "GEM*91 – An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS", Antisense Res. Dev. 2:261-266
A2	Agrawal et al. (1994) "Potential for HIV-1 Treatment with Antisense Oligonucleotides", J. Biotech. in Healthcare, 1(2):167-182.
A3	Agrawal, et al. (1995) "Pharmacokinetics of Antisense Oligonucleotides", Clin. Pharmacokinet. 28(1):7-16
A4	Agrawal (1996) "Preface" in Methods in Molecular Medicine: Antisense Therapeutics (Agrawal,ed.) pp. v-vii
A5	Agrawal, et al. (1998) "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals", in <u>Handbook of Experimental Pharmacology</u> , Vol. 131: Antisense Research and Application, Springer-Verlag, pp. 525-543
A6	Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," Biochemica et Biophysica Acta 1489:53-68
A7	Beaucage (1993) "Oligodeoxyribonucleotides Synthesis" in Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs, (Agrawal, ed.) Humana Press, Totowa, NJ, pp.33-61
A8	Brown (1993) "A Brief History of Oligonucleotide Synthesis" in Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs, "pp. 1-17
A9	Craig et al. (1997) "Patent strategies in the antisense oligonucleotide based therapeutic approach" Exp. Opin. Ther. Patents 7(10):1175-1182
A10	Database CAS Registry (2003), (Date of entry: 1997), Registry number 193635-63-1
A11	Froehler (1993) "Oligodeoxynucleotide Synthesis," Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs (Agrawal, ed.) Humana Press, Towtowa, NJ, pp. 63-80
A12	Furdon (1989) "RNase II cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds," Nucleic Acids Research, Vol. 17:22, pp. 9193-9205
A13	Galderisi et al. (1999) "Antisense Oligonucleotides as Therapeuitic Agents" J. Cell. Physiol. 181:251-257

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. Form PTO-1449		Docket Number	Application Number	
	I DISCLOSUBE	47508-556	09/896,692	
<i>7</i> . 11 ~ \	N DISCLOSURE	(HYZ-069CN2)	<u> </u>	
O , THÍ NH ALF	PLICATION	Applic	eant)
(1)		Agra	wal 🚴 🖍 闩	^
FEB 0 4 2004 Several she	eets if necessary)		10/2 (S)	
<i>≩</i> /		Filing Date	Group Art Un	
Sheet 2	OF 2	June 29, 2001	1635	200
Sheet 2				A
Lisziewicz et a		Human Immunodeficiency Virus Type atment", Proc. Natl. Acad. Sci. USA 89:1		3000
		ent of Human Immunodeficiency Virus-In Natl. Acad. Sci. USA 90:3860-3864	fected Cells with Antisense	40
A16 Lisziewicz et a Replication of 91:7942-7946	f Human İmmunodeficiency Vir	xynucleotide Phosphorothioate Complei us Type 1 in Human Peripheral Blood C	mentary to Gag mRNA Blocks dells", Proc. Natl. Acad. Sci. USA	
	cation," in Prospects for Antiser	AIDS Treatment: An Antisense Approact nse Nucleic Acid Therapy of Cancer and		
A18 Metelev et al. Abstracts, 128	(1998) "HPLC of Oligodeoxyril 8(13):272	oonucleoside Phosphorothioates", Abstr		
ATS Chemistry, 23	3(9):673-677, Translated from E	bonucleoside Phosphorothioates" Russ Bioorganicheskaya Khimiya 23(9):742-7	46	
1937		Antisense Drug Design", Journal of Med		
Biotech. 15:53	37-541	sense Reagents on Combinatorial Oligo		
Biotechnology	y, 68:1-13	elopments for gene therapy of human d		
A23 Tamm, I., et a	al. (Aug. 2001) "Antisense thera	apy in oncology: new hope for an old ide	ea?" The Lancet, 358:489-496	
A25 Zamecnik (19	ii. (1990) "Antisense Oligonucië 196) "History of Antisense Oligo 1 Humana Press, Totowa, NJ, p	otides: A New Therapeutic Principle," Conucleotides" in Methods in Molecular Mole	edicine: Antisense Therapeutics	
Rats," Bioche	em. Pharmacol. 50(4): 545-556	ition and Metabolism of a "Hybrid" Oligo		
Phosphorothic	oate (GEM 91) in HIV-Infected	Anti-Human Immunodeficiency Virus An Subjects", <i>Clin. Pharmacol. Ther.</i> 58(1)	:44-53.	
A28 Phosphorothic	1996) "Pharmacokinetics and loate in Rats After Intravenous 278(2):971-979	Fissue Disposition of a Chimeric Oligode Administration," Journal of Pharmacolog	eoxynucleoside gy and Experimental	
		rity of CpG Containing Phosphorothioate rnucleoside", <i>Bioorganic & Medicinal Ch</i>		
EXAMINER		DATE CONSIDERED		

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.